AM23 (@AM231982) profile picture

Avacta, Aston Martin, Formula 1

City of London, London
Joined July 2018
Photo by AM23 (@AM231982)Photo by AM23 (@AM231982)Photo by AM23 (@AM231982)Photo by AM23 (@AM231982)Photo by AM23 (@AM231982)Photo by AM23 (@AM231982)Photo by AM23 (@AM231982)Photo by AM23 (@AM231982)Photo by AM23 (@AM231982)Photo by AM23 (@AM231982)
In 2 days #AVCT present AVA6207 its Next Generation pre|CISION dual payload PDC (peptide drug conjugate) at EORTC-NCI-AACR. This is significant. GLOBALLY - There are zero dual payload PDCs in clinical trials. - There are Zero dual payload PDCs which have cleared IND studies - Zero ATR inhibitors have been approved by the FDA Avacta are preparing AVA6207 for IND enabling studies Even the computer knows the context here. 'Avacta Therapeutics holds the most advanced publicly disclosed program with AVA6207, a third-generation pre|CISION® dual-payload PDC delivering a topoisomerase I inhibitor (TOP1i) and an ATR inhibitor (ATRi)' What do you think happens to tumours when you take the most potent TOP1i in it's class Exatecan, (a drug pharma failed to harness for decades) and then add an ATR Inhibitor to stop DNA repair? There are a long list of reasons Avacta will likely be the first company globally to have a dual payload PDC in clinical trials. The obvious one is that pharma have failed to harness Exatecan and its systemic toxicity. Avacta have cracked the safety and tolerability because of pre|CISION a delivery mechanism which pharma simply don't have. The stage is set, the strategy in play....do pioneering things with assets pharma can't harness and make them pay big. AVA6103 could be the largest revenue generating oncology drug when considering the total addressable market (TAM) potential of the 8 indications on the current trial. AVA6207 could be even more valuable and that is what is at stake here. 2 days and we learn which ATRI payload is being used and who the likely pharma owner of that asset is. 2+2=4 and has always been the case.
4
16
2
96
4,163
AM23 retweeted
#AVCT AVA6103 Safety ✅ Extended release ✅ PK alignment ✅ Exatecan in the tumours ✅
1
6
64
3,897
AM23 retweeted
#AVCT Did you see that smile from Ruairidh?! (Bear in mind they have biopsies in hand) 💥💥💥
5
27
3
94
10,102
AM23 retweeted
#AVCT releases the warheads which will make up AVA6207 next week. The foundation of AVA6207 is AVA6103. Now proven in human. Ownership of the ATR inhibitor, which will sit alongside Exatecan in AVA6207, will be highly informative. Who owns the green payload AVCT seeks to use?
2
11
79
3,611
Replying to @RAH00084
Only 2-4 months until the wider market starts to perceive that #AVCT's AVA6103 could genuinely become a $20bn, $30bn, >$40bn per annum drug. The best selling oncology drug in history. That is, until the data for AVA6207 begin to emerge...!
4
12
2
110
8,375
AM23 retweeted
#AVCT Cohort 1 Began end of March On 10 September, two patients remained on drug. That’s 5.5 months of disease stabilisation across stage 4 pancreatic cancer patients. Achieved with a 1.5mg dose of AVA6103. I.e. their tumours are not seeing progression. Cohort 2 Began ~mid May On 10 September, five patients remained on drug. That’s ~4 months of disease stabilisation across stage 4 pancreatic/CRC/cervical cancer patients. Achieved with a 3mg dose of AVA6103. I.e. their tumours are not seeing progression Cohort 3 Began ~early July On 10 September, (all) seven patients remained on drug. That’s ~2.5 months of disease stabilisation across stage 4 pancreatic/CRC/breast patients. Achieved with a 4.5mg dose of AVA6103 I.e. their tumours are not seeing progression Cohort 4 Began began ~mid August Dosing 6.8mg. Just below the Enhertu equivalent. Cohort 4 has completed enrolment as of 23 October. Enrollment is ongoing in both arms of the study. 8 months into trial end of November. It is quite clear AVA6103 is working. In human. Funded well into May 2027. That’s ~7 months of funding after a 68p fundraise which saw the directors take £660k. Cohort 5 (current cohort) projected to match the absolute dose of Enhertu. Q2W scanned every 8 weeks. Q3W scanned every 6 weeks. Couple of biopsies up their sleeves. They know exactly what this drug is doing 7.5 months into trial. The amount of ‘ hot takes’ I’ve read which are concerned about “funding into May when AVA6103 efficacy is not due to H1 2027” demonstrates enormous naivety. For two reasons: (1) the trial is flying, you’ll see efficacy early H1 2027 at this rate; (2) the efficacy data (as a package) for AVA6103 is actually irrelevant for the assets AVCT is seeking to deal on: a 3rd party warhead; AVA6000; AVA6207. Yes, the AVA6103 data supports the negotiations but they are not dealing on AVA6103. Proving AVA6103 is working (to the extent the tech can transfer to a third party warhead) was done when they RNS’ed preCISION was proven. Partners will receive this data under NDA on a constant basis. Far more important are the commercials of those deals, which improve as the AVA6103 data grows. That is to say the 6103 data *supports* the value discussion, rather than being the arbiter of any deal(s). Crazy thought I know, but they have a strategy. X3 separate deal avenues to deal on before May 2027. Lots of noise. Little logic.
1
13
77
6,685
#AVCT Advance further into pioneering oncology..... A dual payload to be presented at EORTC in 2 weeks time. This is highly significant. A very high chance the second payload is pharma owned = Deal time. There are only 3 dual payload ADC drugs in the clinic globally. Zero Dual PDCs which Avacta specialise in. First mover advantage in dual payload PDC's another first. They really are at the tip of the spear here adding an ATRI inhibitor to inhibit resistance mechanisms. Pair that with Exatecan used in the AVA6103 trial and you you have a lethal cocktail pharma can only dream of before Avacta's arrival. avacta.com/avacta-to-present… 1/2
4
21
2
123
8,345
2/2 So in just a few short years Avacta have.... 1. Removed cardio toxicity from Doxorubicin - A 50 year problem pharma failed to address. 2. The FDA removed the lifetime limit of AVA6000 which uses Doxorubicin as the warhead. This was the first time ever in a P1A trial a lifetime limit had been removed! 3. Then taken the most potent drug in its class Exatecan again one pharma could not harness at full strength and completely changed its safety and tolerability profile, its therapeutic index and half life. 4. Now takes Exatecan and pairs it with an ATRI inhibitor!! The key differentiator here is 'Precision' the Avacta tumour targeting and delivery mechanism which just so happens to works on 90% of all solid tumours!!!!They have cracked the safety and tolerability limitations which is still a prolific problem for pharma. This enables them to target the tumour more successfully, deliver the payload to the tumour and see a significant reduction in typical toxicities. Precision is checkmate for so much of the current industry thinking. Well done the AVCT a team of 20-25 people has done all that!!
3
14
2
117
3,269
Market is acting like #AVCT is funded into December 2026, rather than May 2027. A lot can happen in a very short time in biotech. And Avacta has x5 shots on goal: AVA6000 (SGC) AVA6000 (TNBC) AVA6103 (multiple shots) AVA6207 (also multiple shots) PRECISION (to a 3rd party warhead) Never been more confident - today buying Avacta is the cheapest and safest that it has ever been. So I did !
4
11
101
3,326
AM23 retweeted
3
5
51
4,147
Over to #AVCT…..pretty sure they will have something to say here….!!! A very well timed article. They don’t like talking about the constraints of Enhertu but Avacta does with confidence regularly now. They know!!! “To design a molecule stronger than Enhertu in HER2-positive breast cancer, I think maybe we can design it on paper, but to clinically prove it is stronger is just too difficult,” he said. fiercebiotech.com/biotech/ad…
4
10
1
69
5,878
AM23 retweeted
#AVCT’s AVA6103 works. “Mechanistically, the sustained release mechanism is playing out as we expect.” “Findings increase confidence that the nonclinical-to-clinical translation is performing as intended - exactly as we anticipated.”
Watch episode 16 of our R&D Spotlight series, where Avacta Chief Executive Officer @coughlin582 takes a deep dive into the AVA6103 data presented at ESMO 2026. avacta.wistia.com/s/xs4ra3k8… #AVCT
1
14
90
3,586
AM23 retweeted
#AVCT Novartis bought FAP2286 from Clovis in bankruptcy. $50m upfront; $333.75m in regulatory milestones (split equally between P1b; P2; P3); $297m in future sales payments. FAP2286 had dosed 11 patients at the time of sale. Efficacy: 1 patient of the 11 treated in Phase 1 saw a partial response. Safety: 45.5% of patients saw Grade 3/4 adverse events. You'll struggle to find a better representation of how cheap AVCT (£311m) is today than this sale. Achieved in bankruptcy. X2 drugs in clinic, north of 150 patients dosed across those programmes. A clear USP. Going after ADCs. Safety impeccable. No loss of activation enzyme on tumour destruction. AVCT could down all tools tomorrow, put the entire Co up for auction and sell for multiples of today’s SP. Funny old market. I’m a buyer here. AVA6103 is currently reading out critical C3 data (and every oncologist linked to the trial is promoting their collaboration…).
2
11
79
3,222
Another outstanding update from #AVCT this morning. AVA6000 has been quietly ticking off it's list of achievements. 1. Standard Doxorubicin has a lifetime limit precisely because of cardio toxicity. The impact is a limit on treatment cycles 4-6 dependent on dose. The answer is Avacta's AVA6000 = Zero cardio toxicity, many more cycles 12 referenced in the RNS today = more time with your family and reduced toxicity. 2. AVA6000 is the first drug EVER to have the lifetime limit removed by the FDA in a phase 1 trial. Think about that. 3. AVA6000 PFS for SGC nearly doubled and may well improve further. 4. TNBC efficacy seen!! (see poster) Many forget Doxorubicin is used in combo trials as part of keynote 522 along side a $30bn revenue drug Keytruda which comes off patent in 2028...Merck have a massive patent cliff approaching. It is used as Dox is effective! 5. As the first ever Precision drug it has proven the IP works in the clinic. AVA6103 further enhances the wider platform capability. The FDA endorsements will keep coming as the story unfolds imo. Rinse and repeat. Many forget the positives of AVA6000 because the trial was a victim of it's own success...could not find an MTD, a 5yr phase 1 trial and not yet partnered but it has set a new standard that only demonstrates further there is a huge void to fill which will improve patient care with Precision drugs. At some point soon we will be playing a game of 'Knock Knock'....'Who's there?'
3
18
1
119
3,572
AM23 retweeted
#AVCT AVA6000 contains a peptide. That peptide masks doxorubicin to the extent an 80 year old suffering from triple negative breast cancer is able to safely receive preCISION-doxorubicin. And work. The risks of chemotherapy induced toxicity due to reduced organ reserve, comorbidities and general frailty for an 80 year old are clear. Yet it’s working. Quite clearly. Why is it working? It has an exceptional safety profile. Due to this peptide’s exceptional specificity. Now consider the same peptide is in AVA6103. AVA6103 has an additional modified capping group and a linker (which are designed to sustain the release of Exatecan for days, rather than hours). We know from the human PK to date, that is exactly what AVA6103 is doing (with exceptional alignment between pre-clinical and clinical data). It’s extending release of Exatecan because the capping group and linker are working. In human. It’s safe because the peptide (employed in both AVA6000 and AVA6103) is so specific. We have seen the clean safety profile through cohorts 1-3 of AVA6103. Thanks to the peptide. We have seen the FDA remove the dosing limit (for the first time in the history of a P1 drug) in AVA6000. Thanks to the peptide. We are now seeing just how safe this peptide makes toxic drugs. 5 & 1/4 years of combined data back this up across Top1 and Top2 inhibitors. Tomorrow AVA6103 will be 30 weeks into clinic. Tomorrow AVCT will outline how AVA6000 is demolishing the benchmark in Salivary Gland Cancer. A prolonged median PFS of 11.4 months. That is nearly doubling the benchmark in the first and second line setting (both chemotherapy and targeted therapy). AVA6000 in SGC deals on this PFS. Quite clearly. In addition to all this, I can’t help but wonder whether AVA6000 in TNBC is going to also find a partnership with generic Keytruda in the future. Patent expiry in 2028? $30+Bn pa drug. Often used in tandem with doxorubicin which has now been made safe by preCISION. Keynote 522(P)? The trial Coughlin said she would most like to run for 6000. AVA6207 on the cusp of revealing its warheads. AVA6103 biopsies incoming. AVA6000 demolishing the PFS in SGC. Looking forward to hearing more about FAP recruitment, durability and the real world impact of AVA6000 when the company explains the findings to the market tomorrow. ‘Bloody science project’.
5
26
1
170
8,545
We are delighted to present 2 data sets at #ESMO26 - #AVCT Trials in Progress with AVA6103 shows some critical platform data showing mechanistic evidence for fibroblast recruitment, rapid and deep tumor penetration and enhanced payload exposure over traditional ADC #LetsDoThis
At #ESMO26, we’re presenting the FOCUS-01 trial design and new preclinical data for AVA6103 (FAP-Exd), our first Next Gen pre|CISION® PDC, including activity in Enhertu®-resistant tumor models. avacta.com/avacta-highlights… #preCISION #NextGenLoading #AVCT
2
30
4
232
9,987
AM23 retweeted
Most important sentence in an #AVCT RNS for a long while. We’re home. Nearly dry. 🚀
8
78
2,643
I'm increasingly excited about Avacta #AVCT because I genuinely believe the next eight to twelve weeks could be transformational. As everyone knows, they've developed a technology that allows incredibly powerful drugs to be delivered much more precisely to 1/23
4
13
2
93
7,857
Another outstanding performance from Chris on Thursday. #AVCT When you know you know and she definitely KNOWS! 1. FDA approved the removal of the life time allowance on a 50yr old chemo drug Doxorubicin in a Phase 1A safety trial last year. AVA6000 was the first drug ever to have achieved this in P1A….. 2. You then harness Exatecan aka ‘The Beast’ the most potent drug in its class where pharma failed to tame its toxicity for years. AVA6103 is that Precision drug now in clinical trials. 3. You state you can put almost any warhead on precision the delivery mechanism and have hundreds of options in the locker. 4. You compare your safety profile to a $5bn per year blockbuster drug Enhertu only months into your AVA6103 trial and blitz it! 5. You don’t sign up a dozen premier US trial sites if AVA6103 wasn’t working! Chris Coughlin @coughlin582 will be remembered as leading a small team of incredible talents who redefined what was possible and made it happen. Imagine you get diagnosed with this awful disease but there are new treatment options where the historical fear of awful side effects is no longer a fear as the standard of care is a Precision drug, where you can safely have more doses or higher doses giving you the best chance of survival at the same time. I believe the next few months will establish Avacta as the most disruptive company most have never heard of on the ADC/ oncology landscape. Most forget P1A patients are typically end of life who are prepared to aid science by their selfless acts to ensure others have a tomorrow. What Heroes! Thank you.
2
31
4
224
13,327
AM23 retweeted
When Richard Hughes joined #AVCT as a NED on 28 May 2025, @avacta’s m.cap sat at £135m (£25.5m CLN outstanding) The m.cap of AVCT today is £312m with £12m outstanding on the CLN. The company’s growth during this period has been undeniable (+131%).
3
26
1
73
5,791